FibroGen(US:FGEN)2026-03-16 22:02Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024 [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024 [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - Total operating costs and expenses for the full year 2025 were $52.3 million, down from $180 million in 2024 [23] - R&D expenses for Q4 2025 were $7.3 million, compared to $6.9 million in Q4 2024 [24] - R&D expenses for the full year 2025 were $23.5 million, down from $95.7 million in 2024 [24] - SG&A expenses for Q4 2025 were $7.3 million, compared to $8.3 million in Q4 2024 [24] - SG&A expenses for the full year 2025 were $27.7 million, down from $49.3 million in 2024 [24] - The net loss from continuing operations for Q4 2025 was $14.6 million, compared to a net loss of $8.7 million in Q4 2024 [25] - The net loss from continuing operations for the full year 2025 was $58.2 million, compared to a net loss of $153.1 million in 2024 [25] - As of December 31, 2025, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [7][8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease [7] - Current treatments for anemia associated with lower-risk MDS are effective in less than 50% of patients, highlighting the need for new therapies [18] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company plans to initiate a phase III trial for roxadustat in the second half of 2026 [21][27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway [26] - The company remains confident in its clinical programs and the potential for FG-3246 and FG-3180 to provide meaningful therapeutic options [7][27] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of seven years of regulatory exclusivity [22] - The company is actively enrolling patients for the FG-3246 phase II trial and expects interim results in the second half of 2026 [15][27] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the positioning of CD46 PET imaging agents in relation to existing PSMA agents and the anticipated commercial opportunity [30][32] Question: SUV data and patient selection - Management addressed the correlation between SUV data and patient selection, noting the need to define CD46 positivity metrics in the phase II trial [30][40] Question: Balance of patients in studies - Management clarified that the phase II monotherapy trial will focus on patients who have progressed on one prior ARPI, differentiating from the IST [46] Question: Updates on roxadustat partnering efforts - Management indicated ongoing evaluations for internal development versus potential collaborations for roxadustat but did not provide specific updates [49] Question: Delay in FDA feedback for roxadustat - Management explained the expected timeline for FDA feedback on the IND submission, indicating a 60-90 day period for response [53][54]